Vincristine
Tubulin Inhibitor
DB00541
Approved Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
2
Targets
0
Resistance Mutations
4
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca<sup>2+</sup>-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
Details
DrugBank ID
DB00541 ↗
Approval Date
1988-04-19
Molecular Weight
824.9576 g/mol
Drug Class
Tubulin Inhibitor
ATC Codes
L01CA02
Synonyms
22-Oxovincaleukoblastin, 22-Oxovincaleukoblastine, Leurocristine
PubChem
CID: 5978 ↗
ChEMBL
CHEMBL90555 ↗
SMILES
[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC)[C@]1(C[C@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC
ADMET Profile
Computing properties…
Drug References (DrugBank)